Bristol-Myers Squibb Company (BMY)

78.83
-1.05(-1.31%)
After Hours
78.80
-0.03(-0.04%)
- Real-time Data
  • Volume:
    8,829,142
  • Day's Range:
    78.73 - 80.67
  • 52 wk Range:
    57.11 - 81.43

BMY Overview

Prev. Close
79.88
Day's Range
78.73-80.67
Revenue
46.48B
Open
80.13
52 wk Range
57.11-81.43
EPS
3.1
Volume
8,829,142
Market Cap
174.97B
Dividend (Yield)
2.16
(2.74%)
Average Volume (3m)
9,590,257
P/E Ratio
25.63
Beta
0.389
1-Year Change
37%
Shares Outstanding
2,219,644,935
Next Earnings Date
Feb 01, 2023
What is your sentiment on Bristol-Myers Squibb?
or
Market is currently closed. Voting is open during market hours.

Bristol-Myers Squibb Company News

Bristol-Myers Squibb Company Analysis

Bristol-Myers Squibb Company Company Profile

Bristol-Myers Squibb Company Company Profile

Employees
32200

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Read More

Analyst Price Target

Average79.26 (+0.55% Upside)
High90.00
Low60.00
Price78.83
No. of Analysts23
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellBuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellBuyStrong Buy
SummaryStrong SellStrong SellStrong SellBuyStrong Buy